What does a serum follicle‑stimulating hormone (FSH) level of 137 IU/L indicate in a female, and what are the appropriate management steps?

FSH 137 IU/L in a Female: Diagnosis and Management

An FSH level of 137 IU/L in a female indicates established premature ovarian insufficiency (POI) or menopause, and requires immediate initiation of hormone replacement therapy (HRT) with 17-beta estradiol to prevent cardiovascular disease, osteoporosis, and premature mortality.

What This FSH Level Means

An FSH of 137 IU/L is markedly elevated and diagnostic of ovarian failure. According to current guidelines, FSH levels >25 IU/L in a woman under 40 years (outside of the pre-ovulation peak) indicate POI 1. Your patient's level of 137 IU/L far exceeds this threshold and confirms severe ovarian dysfunction.

Confirm the Diagnosis

Before proceeding, you must:

• Repeat FSH measurement in 1 month along with estradiol and prolactin to confirm the diagnosis 1
• Ensure the patient is not on combined oral contraceptives or progestins, as these suppress FSH and give falsely low readings; if she is, wait 3 months after discontinuation before retesting 1
• Check that estradiol is low (ruling out pre-ovulation peak or estradiol-secreting cyst) 1
• Obtain pregnancy test (hCG) to exclude pregnancy 1

Critical Next Steps: Assess Age and Etiology

If Patient is Under 40 Years: This is POI

Conduct a focused evaluation:

History to obtain:

• Family history of POI or early menopause
• Prior ovarian/pelvic surgery
• Chemotherapy or pelvic radiation exposure
• Autoimmune conditions: thyroid disease, diabetes, Addison's disease, vitiligo, celiac disease, rheumatoid arthritis
• Family history of fragile X syndrome or intellectual disability in males 1

Physical examination for:

• Signs of Turner syndrome (if not previously diagnosed)
• Vasomotor symptoms (hot flashes, night sweats)
• Vaginal atrophy
• Autoimmune stigmata 1

If Patient is Over 50 Years: This is Natural Menopause

The management approach differs slightly but HRT remains indicated if symptomatic or for prevention of long-term complications.

Immediate Treatment: Hormone Replacement Therapy

The single most important intervention is starting HRT immediately to reduce mortality and morbidity 2, 1. Without HRT, women with POI face:

• 80% increased risk of death from ischemic heart disease compared to women with menopause at age 49-55 1
• Accelerated bone loss and osteoporosis, especially if peak bone mass was not achieved 1
• Significantly reduced quality of life and psychological wellbeing 2

HRT Regimen

Preferred estrogen: 17-beta estradiol (NOT ethinyl estradiol or conjugated equine estrogens) 2, 1

Preferred route: Transdermal (patch) to avoid first-pass hepatic metabolism and minimize VTE risk 2, 1

Dosing:

• Start with 100 mcg transdermal patch or 2 mg oral 17-beta estradiol 1
• Adjust based on symptom control and estradiol levels

Add progestogen if the patient has an intact uterus to protect the endometrium 2, 1:

• Micronized progesterone is preferred, though cyclical combined treatment has the strongest evidence for endometrial protection 2

Duration: Continue HRT at least until age 51 years (average age of natural menopause) 2, 1

Special Considerations for HRT

• Hypertension is NOT a contraindication; use transdermal estradiol preferentially 2, 1
• Obesity/overweight: Use transdermal estradiol 1
• History of VTE or thrombophilia: Refer to coagulation specialist; if HRT approved, use transdermal route 1
• Breast cancer risk: Reassure the patient that HRT does NOT increase breast cancer risk before the age of natural menopause 2, 1

If Contraception is Needed

Combined oral contraceptives (COCs) can provide both hormone replacement and contraception, as spontaneous pregnancy remains possible in 4-6% of POI cases 1. However, transdermal estradiol is superior for cardiovascular and bone protection.

Additional Management

Cardiovascular Risk Assessment

Monitor annually:

• Blood pressure
• Weight
• Smoking status
• Lipid profile (especially in Turner syndrome)
• Fasting glucose and HbA1c (especially in Turner syndrome) 2, 1

If Turner syndrome is diagnosed, refer to a cardiologist with expertise in congenital heart disease 2.

Bone Health

• Assess bone mineral density (BMD) at diagnosis
• Encourage weight-bearing exercise, smoking cessation, and healthy weight 2
• HRT is the primary bone protection strategy 2

Psychological Support

POI has profound negative impacts on quality of life and psychological wellbeing 2. Provide access to psychological counseling and lifestyle interventions 2.

Fertility Counseling

If the patient desires future pregnancy:

• Explain that spontaneous pregnancy occurs in 4-6% of cases but is unpredictable 1
• Discuss oocyte donation as the most reliable option for conception 1
• If FSH remains >20 IU/L, ovarian stimulation is unlikely to be successful 1

Common Pitfalls to Avoid

1. Delaying HRT initiation: This increases cardiovascular and bone disease risk. Start immediately after diagnosis confirmation.
2. Using oral contraceptives as sole HRT in older patients: While acceptable for young women needing contraception, transdermal estradiol is superior for cardiovascular protection 1.
3. Stopping HRT before age 51: Many women discontinue therapy due to misconceptions about breast cancer risk 1. Educate patients that HRT is protective, not harmful, before natural menopause age.
4. Failing to add progestogen: In women with a uterus, unopposed estrogen increases endometrial cancer risk 2.

Annual Follow-Up

Once HRT is established:

• Clinical review annually focusing on compliance 2, 1
• Gynecologic examination, breast palpation, weight, and blood pressure 1
• No routine hormone monitoring is needed unless specific symptoms arise 2

211111